Canagliflflozin (Cana), an SGLT2 inhibitor used to treat DN, is an important protein that protects the kidney from fibrosis by inhibiting FTO and increasing the stability of SQSTM1 (Yang et al. 2022). This evidence concerns the gene FTO and liver dysplastic nodule.